A Study of LY3361237 in Participants With Systemic Lupus Erythematosus

Inclusion Criteria

• •Participants must have received a diagnosis of SLE at least 24 weeks before screening (at least 4 of 11 criteria in 1997 revised American College of Rheumatology \[ACR\] classification)
• •If a participant is taking oral prednisone (or prednisone equivalent) for SLE, the dose must be ≤20 milligrams per day (mg/day) for at least 8 weeks prior to screening, and must have been stable for at least the last 2 weeks
• •If a participant is taking any of the following medications for SLE, the medication must have been used for at least 12 weeks and stable for at least the last 8 weeks:
• •* Azathioprine ≤200 mg/day
• •* Antimalarial (e.g., chloroquine, hydroxychloroquine, quinacrine)
• •* Mycophenolate mofetil ≤2 g/day or mycophenolic acid ≤1.44 grams per day (g/day)
• •* Oral, SC, or intramuscular methotrexate ≤15 milligrams per week (mg/week)